Enwei Pharmaceutical Co., Ltd. (SHE:301331)

China flag China · Delayed Price · Currency is CNY
28.57
+0.72 (2.59%)
At close: Mar 10, 2026
13.60%
Market Cap 2.89B
Revenue (ttm) 888.64M
Net Income (ttm) 52.06M
Shares Out 101.08M
EPS (ttm) 0.52
PE Ratio 54.82
Forward PE n/a
Dividend 0.35 (1.23%)
Ex-Dividend Date Jan 8, 2026
Volume 753,098
Average Volume 1,868,679
Open 28.39
Previous Close 27.85
Day's Range 27.73 - 28.60
52-Week Range 21.64 - 39.66
Beta 0.62
RSI 49.72
Earnings Date Apr 27, 2026

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd. engages in the development and sale of Chinese medicines in China. The company offers drugs in the areas of gynecology, pediatrics, and respiratory system fields. The company was founded in 2005 and is based in Chengdu, China. [Read more]

Sector Healthcare
Founded 2005
Employees 1,548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301331
Full Company Profile

Financial Performance

In 2024, Enwei Pharmaceutical's revenue was 812.13 million, an increase of 3.43% compared to the previous year's 785.19 million. Earnings were 37.50 million, a decrease of -56.56%.

Financial Statements

News

There is no news available yet.